[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100547923":3},{"organization":4,"outcomesModule":7,"designInfo":14,"detailedDescription":17,"studyPopulation":18,"armGroups":19,"interventions":25,"overallOfficials":30,"centralContacts":13,"locations":34,"responsibleParty":55,"collaborators":57,"id":61,"slug":13,"hasResults":62,"nctId":63,"briefTitle":64,"officialTitle":65,"acronym":13,"eligibilityCriteria":66,"healthyVolunteers":62,"sex":67,"minAge":68,"maxAge":13,"enrollmentInfo":69,"targetDuration":13,"studyType":72,"phases":13,"briefSummary":73,"conditions":74,"keywords":13,"overallStatus":37,"whyStopped":13,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":86},{"fullName":5,"class":6},"Masonic Cancer Center, University of Minnesota","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":13},[9],{"measure":10,"description":11,"timeFrame":12},"Proportion of patients completing at least 80 percent of planned SALSA administrations during post CAR-T hospitalization","Descriptive statistics will be used to summarize the feasibility of SALSA in CAR-T patients. The overall completion rate of will be calculated for each patient, as well as the pattern of completions.","18 months",null,{"allocation":13,"interventionModel":13,"interventionModelDescription":13,"primaryPurpose":13,"observationalModel":15,"timePerspective":16,"maskingInfo":13},"COHORT","PROSPECTIVE","PRIMARY OBJECTIVES:\n\nI. To investigate the use of a toolkit for automated administration and scoring of cognitive tests (Stress, Language and Speech Analysis, or SALSA) in adult cancer patients who are treated with commercial chimeric antigen receptor T cell therapy (CAR-T) products at University of Minnesota and are at risk of developing immune effector cell-associated neurotoxicity syndrome (ICANS).\n\nOUTLINE: This is an observational study.\n\nPatients complete SALSA assessment and ICE assessments on study. Patients also have their medical records reviewed on study.","Patients planning to undergo CAR-T therapy for primary malignancy recruited through the University of Minnesota.",[20],{"label":21,"type":13,"description":22,"interventionNames":23},"Observational","Patients complete SALSA assessment and ICE assessments on study. Patients also have their medical records reviewed on study.",[24],"Other: Non-Interventional Study",[26],{"type":6,"name":27,"description":28,"armGroupLabels":29,"otherNames":13},"Non-Interventional Study","Non-interventional study",[21],[31],{"name":32,"affiliation":5,"role":33},"Veronika Bachanova","PRINCIPAL_INVESTIGATOR",[35],{"facility":36,"status":37,"city":38,"state":39,"zip":40,"country":41,"countryCode":42,"cosmosGeoPoint":43,"geoPoint":48,"contacts":49},"University of Minnesota\u002FMasonic Cancer Center","RECRUITING","Minneapolis","Minnesota","55455","United States","US",{"type":44,"coordinates":45},"Point",[46,47],-93.26384,44.97997,{"lat":47,"lon":46},[50,54],{"name":32,"role":51,"phone":52,"phoneExt":13,"email":53},"CONTACT","612-625-5469","bach0173@umn.edu",{"name":32,"role":33,"phone":13,"phoneExt":13,"email":13},{"type":56,"investigatorFullName":13,"investigatorTitle":13,"investigatorAffiliation":13,"oldNameTitle":13,"oldOrganization":13},"SPONSOR",[58],{"name":59,"class":60},"National Cancer Institute (NCI)","NIH","100547923",false,"NCT06414278","Evaluation of Early Identification of Cognitive Side Effects of Immunotherapy","Early Identification of Cognitive Side-Effects of Immunotherapy","Inclusion Criteria:\n\n* \\* ≥ 18 years of age at initiation of therapy\n\n  * Planning to undergo inpatient CAR-T therapy for primary malignancy\n  * Fluent in English (written or spoken)\n\nExclusion Criteria:\n\n* \\* Subjects with speech or hearing impediment that would make them unable to be assessed with SALSA\n\n  * Subjects with diagnosed cognitive impairment prior to CAR-T therapy\n  * Unwilling or unable to sign voluntary written consent","ALL","18 Years",{"count":70,"type":71},38,"ESTIMATED","OBSERVATIONAL","This clinical trial evaluates the use of a tool kit, Stress, Affect, Language and Speech Analysis (SALSA), for early identification of cognitive side effects of immunotherapy compared to the standard of care assessment.",[75,76],"Hematopoietic and Lymphatic System Neoplasm","Malignant Solid Neoplasm","2026-01-12",{"date":79,"type":80},"2026-01-13","ACTUAL",{"date":82,"type":80},"2024-02-08",{"date":84,"type":71},"2028-02-21",{"name":5,"class":6},1]